{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:08:16Z","timestamp":1785431296298,"version":"3.56.0"},"reference-count":28,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA044579"],"award-info":[{"award-number":["P30 CA044579"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This randomized phase I\/II clinical trial (NCT03617328) was designed to test whether administration of systemic agonistic anti-CD27 antibody (varlilumab) concurrent with a melanoma vaccine is safe and enhances vaccine immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Adults with definitively treated, high-risk melanoma were randomized to receive a shared antigen vaccine targeting CD4+ T cells (6 melanoma helper peptides; 6MHP) either with (arm A) or without (arm B) systemic varlilumab over 11 weeks. A final vaccine was given at week 25 to assess memory response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty-three participants were treated at two centers. After enrolling 17 participants, the dose-limiting toxicity (DLT) rate with vaccine alone required protocol revision to limit local toxicity. Overall, DLT rates for arms A and B were 6% (1\/17) and 31% (5\/16), respectively. Twenty (61%) participants had CD4+ T-cell responses ex vivo. Persistent responses were detected in two (2\/14, 14%) on arm A and one (1\/16, 6%) on arm B. Memory response was detected in two (2\/13, 15%) on arm A and four (4\/16, 25%) on arm B. On arm A, there was a significant reduction in circulating CD4+ T cells. Four-year disease-free survival rates for arms A and B were 20% [95% confidence interval (CI), 6%\u201367%] and 69% (95% CI, 49%\u201396%), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>No synergistic toxicity was observed with combination treatment. Similar durability in immunogenicity was found with or without varlilumab. Depletion of circulating CD4+ T cells with varlilumab may have abrogated benefits of inducing tumor-cognate CD4+ T cells with vaccination. Induction of memory responses supports further work to optimize shared antigen vaccines in combination with other immunotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Combination treatment with 6MHP vaccination and varlilumab was safe but did not improve CD4+ T-cell response rates. Circulating CD4+ T cells were reduced with varlilumab, and clinical outcome was improved without varlilumab. This study demonstrates induction of memory responses after shared antigen vaccination; however, CD27 agonism did not enhance durability of response. Depletion of CD4+ T cells after varlilumab may have interfered with the beneficial effects of vaccination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0744","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:50:16Z","timestamp":1775825416000},"page":"994-1005","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Randomized Phase I\/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2973-9883","authenticated-orcid":false,"given":"Emily K.","family":"Ninmer","sequence":"first","affiliation":[{"name":"1Division of Surgical Oncology, Department of Surgery, and the Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0571-2820","authenticated-orcid":false,"given":"Gina R.","family":"Petroni","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 2 Department of Public Health Sciences, , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-8915","authenticated-orcid":false,"given":"Elizabeth","family":"Gaughan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 3 Division of Hematology and Oncology, Department of Medicine, , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-5037","authenticated-orcid":false,"given":"Andrew S.","family":"Poklepovic","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02nkdxk79","id-type":"ROR","asserted-by":"publisher"}],"name":"Virginia Commonwealth University 4 Division of Hematology and Oncology, Department of Medicine, , Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-7204","authenticated-orcid":false,"given":"Varinder","family":"Kaur","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 3 Division of Hematology and Oncology, Department of Medicine, , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2467-160X","authenticated-orcid":false,"given":"Kathleen","family":"Haden","sequence":"additional","affiliation":[{"name":"1Division of Surgical Oncology, Department of Surgery, and the Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-3671","authenticated-orcid":false,"given":"Kimberly A.","family":"Chianese-Bullock","sequence":"additional","affiliation":[{"name":"1Division of Surgical Oncology, Department of Surgery, and the Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia."},{"name":"5University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3090-0253","authenticated-orcid":false,"given":"Kelly T.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Division of Surgical Oncology, Department of Surgery, and the Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia."},{"name":"5University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2069-8134","authenticated-orcid":false,"given":"Paul","family":"Wright","sequence":"additional","affiliation":[{"name":"1Division of Surgical Oncology, Department of Surgery, and the Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-4489","authenticated-orcid":false,"given":"Jennifer L.","family":"Bryant","sequence":"additional","affiliation":[{"name":"1Division of Surgical Oncology, Department of Surgery, and the Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2273-7771","authenticated-orcid":false,"given":"David","family":"Brighton","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 2 Department of Public Health Sciences, , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6245-9110","authenticated-orcid":false,"given":"Jack A.","family":"Engel","sequence":"additional","affiliation":[{"name":"1Division of Surgical Oncology, Department of Surgery, and the Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-3261","authenticated-orcid":false,"given":"Timothy N.J.","family":"Bullock","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 6 Department of Pathology, , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6664-4373","authenticated-orcid":false,"suffix":"Jr","given":"Craig L.","family":"Slingluff","sequence":"additional","affiliation":[{"name":"1Division of Surgical Oncology, Department of Surgery, and the Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia."},{"name":"5University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026043008012538400_bib1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/CJI.0b013e3181ee238f","article-title":"Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells","volume":"33","author":"Roberts","year":"2010","journal-title":"J Immunother"},{"key":"2026043008012538400_bib2","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-17-3057","article-title":"PD-1 blockade and CD27 stimulation activate distinct transcriptional programs that synergize for CD8+ T-cell-driven antitumor immunity","volume":"24","author":"Buchan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026043008012538400_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1074-7613(01)00236-9","article-title":"Constitutive CD27\/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion","volume":"15","author":"Arens","year":"2001","journal-title":"Immunity"},{"key":"2026043008012538400_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4049\/jimmunol.1900288","article-title":"CD27 promotes CD4+ effector T cell survival in response to tissue self-antigen","volume":"203","author":"Remedios","year":"2019","journal-title":"J Immunol"},{"key":"2026043008012538400_bib5","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2016.70.1508","article-title":"Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors","volume":"35","author":"Burris","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026043008012538400_bib6","doi-asserted-by":"crossref","first-page":"e005147","DOI":"10.1136\/jitc-2022-005147","article-title":"Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors","volume":"10","author":"Sanborn","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026043008012538400_bib7","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-15-3130","article-title":"CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination","volume":"76","author":"Ahrends","year":"2016","journal-title":"Cancer Res"},{"key":"2026043008012538400_bib8","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1007\/s00262-021-02936-1","article-title":"A prime\/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer","volume":"70","author":"McGray","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2026043008012538400_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/neuonc\/noad185","article-title":"A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas","volume":"26","author":"Saijo","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026043008012538400_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2026043008012538400_bib11","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1200\/JCO.2008.17.3161","article-title":"Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens","volume":"26","author":"Slingluff","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026043008012538400_bib12","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1158\/1078-0432.CCR-15-0233","article-title":"Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival","volume":"21","author":"Reed","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026043008012538400_bib13","doi-asserted-by":"crossref","first-page":"e005424","DOI":"10.1136\/jitc-2022-005424","article-title":"Phase I\/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-na\u00efve and PD-1 antibody-experienced patients with melanoma (MEL64)","volume":"10","author":"Vavolizza","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026043008012538400_bib14","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2010.33.8053","article-title":"Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine","volume":"29","author":"Slingluff","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026043008012538400_bib15","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41467-024-46877-6","article-title":"Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial","volume":"15","author":"Ninmer","year":"2024","journal-title":"Nat Commun"},{"key":"2026043008012538400_bib16","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-13-0002","article-title":"A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)","volume":"19","author":"Slingluff","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026043008012538400_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/80877","article-title":"CD27 is required for generation and long-term maintenance of T cell immunity","volume":"1","author":"Hendriks","year":"2000","journal-title":"Nat Immunol"},{"key":"2026043008012538400_bib18","doi-asserted-by":"crossref","first-page":"e000934","DOI":"10.1136\/jitc-2020-000934","article-title":"Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund\u2019s adjuvant, cyclophosphamide, and polyICLC (Mel63)","volume":"9","author":"Slingluff","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026043008012538400_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-60327-811-9_2","article-title":"Autoantibodies against cancer antigens","volume":"520","author":"Gnjatic","year":"2009","journal-title":"Methods Mol Biol"},{"key":"2026043008012538400_bib20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/imt.15.32","article-title":"Targeting the T-cell co-stimulatory CD27\/CD70 pathway in cancer immunotherapy: rationale and potential","volume":"7","author":"van de Ven","year":"2015","journal-title":"Immunotherapy"},{"key":"2026043008012538400_bib21","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.4049\/jimmunol.1000172","article-title":"Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responses","volume":"185","author":"Kurche","year":"2010","journal-title":"J Immunol"},{"key":"2026043008012538400_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00002371-199801000-00003","article-title":"Comparative analysis of the in vivo expression of tyrosinase, MART-1\/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy","volume":"21","author":"Cormier","year":"1998","journal-title":"J Immunother"},{"key":"2026043008012538400_bib23","first-page":"3223","article-title":"Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions","volume":"57","author":"de Vries","year":"1997","journal-title":"Cancer Res"},{"key":"2026043008012538400_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ijc.2910630313","article-title":"Expression of MAGE genes in primary and metastatic cutaneous melanoma","volume":"63","author":"Brasseur","year":"1995","journal-title":"Int J Cancer"},{"key":"2026043008012538400_bib25","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/bjc.1998.646","article-title":"High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma","volume":"78","author":"de Vries","year":"1998","journal-title":"Br J Cancer"},{"key":"2026043008012538400_bib26","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-15-2294","article-title":"Identification of an immunogenic subset of metastatic uveal melanoma","volume":"22","author":"Rothermel","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026043008012538400_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1479-5876-11-89","article-title":"Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer","volume":"11","author":"Wada","year":"2013","journal-title":"J Transl Med"},{"key":"2026043008012538400_bib28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance","volume":"20","author":"Verma","year":"2019","journal-title":"Nat Immunol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0744\/3766107\/crc-25-0744.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/994\/3784564\/crc-25-0744.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/994\/3784564\/crc-25-0744.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:01:50Z","timestamp":1777550510000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/4\/994\/784502\/Randomized-Phase-I-II-Clinical-Trial-of-a-Melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0744","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32705236","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705269","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705257","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705245","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705299","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705311","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705239","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705302","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705308","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705290","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705293","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705281","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705287","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705242","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705275","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705263","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705296","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705284","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705251","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8542108","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}